Necitumumab
Necitumumab (Portrazza) is an antibody added to gemcitabine and cisplatin as first treatment for squamous non-small cell lung cancer that has spread; the benefit is modest and it is little used.
Overview
Necitumumab was approved by the FDA in November 2015 in combination with gemcitabine and cisplatin for first-line metastatic squamous NSCLC, on the SQUIRE trial (1,093 patients) in which adding the antibody produced a small but statistically significant gain in overall survival, while the INSPIRE trial in non-squamous disease was stopped for lack of benefit and excess thromboembolic deaths. The EU authorised Portrazza in 2016 for EGFR-expressing squamous NSCLC. Cardiopulmonary arrest and hypomagnesaemia carry boxed warnings; rash is universal. Immunotherapy-chemotherapy combinations (KEYNOTE-407) have since made it largely obsolete, and it is listed by the NCCN only as an option in selected patients.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2015 | First-line metastatic squamous NSCLC with gemcitabine and cisplatin |
| EU | 2016 | EGFR-expressing locally advanced or metastatic squamous NSCLC with gemcitabine and cisplatin |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Necitumumab" OR ABSTRACT:"Necitumumab" OR TITLE:"Portrazza" OR ABSTRACT:"Portrazza") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Necitumumab, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductAlemtuzumab
Shares Monoclonal antibodies and the tag nci-list.
- ProductOfatumumab
Shares Monoclonal antibodies and the tag nci-list.
- ProductSiltuximab
Shares Monoclonal antibodies and the tag nci-list.
- ProductIbritumomab tiuxetan
Shares Monoclonal antibodies and the tag nci-list.
- ProductDabrafenib
Shares Non-small-cell lung cancer and the tag nci-list.
- ProductTrametinib
Shares Non-small-cell lung cancer and the tag nci-list.
- ProductRaloxifene
Shares Eli Lilly (incl. Loxo) and the tag nci-list.
- ProductDenosumab
Shares Monoclonal antibodies, Non-small-cell lung cancer and the tag nci-list.